Aulos Bioscience CEO Aron Knickerbocker discusses his company's antibody approach to IL-2 at #ASCO24
Aron Knickerbocker describes the benefits of focusing on the CD-25 binding portion of IL-2 and discusses some data presented at ASCO. He believes this program is the first AI designed human antibody to enter the clinic.